Skip to main content
curacle co., ltd. logo

curacle co., ltd. — Investor Relations & Filings

Ticker · 365270 ISIN · KR7365270008 KO Professional, scientific and technical activities
Open in API
Filings indexed 203 across all filing types
Latest filing 2022-09-26 Regulatory Filings
Country KR South Korea
Listing KO 365270

About curacle co., ltd.

http://www.curacle.com/eng/main/

Curacle Co., Ltd. is a clinical-stage biopharmaceutical company focused on the research and development of innovative drugs for intractable vascular diseases. The company's core platform technology centers on developing highly effective protectors against endothelial dysfunction, a key factor in various age-related and vascular conditions. Its development pipeline includes novel treatments targeting significant unmet medical needs, with a particular focus on conditions such as Diabetic Macular Edema (DME), Wet Age-related Macular Degeneration (wet AMD), diabetes, and stroke. Curacle aims to create differentiated therapies through innovative targets and treatment concepts, including the development of orally administered medications for complex eye diseases.

Recent filings

Filing Released Lang Actions
투자판단관련주요경영사항(당뇨병성 황반부종 치료제(CU06) 미국 FDA 제2a상 임상시험계획(IND) 승인)
Regulatory Filings Classification · 100% confidence The document is a regulatory filing from the Korean Exchange (KRX) system, specifically a 'Major Management Matter' disclosure regarding the approval of a Phase 2a clinical trial (IND) by the US FDA for the company Curacle. Since this is a specific regulatory announcement regarding clinical trial progress and does not fit into the other specialized categories like financial reports or shareholder meetings, it is classified as a Regulatory Filing (RNS).
2022-09-26 Korean
투자판단관련주요경영사항(당뇨병성 황반부종 치료제(CU06) 미국 FDA 제2a상 임상시험계획(IND) 신청)
Legal Proceedings Report Classification · 100% confidence The document is a regulatory filing from the Korean stock exchange (KIND) regarding a 'Major Management Matter' (투자판단 관련 주요경영사항). It details the submission of an Investigational New Drug (IND) application to the US FDA for a Phase 2a clinical trial. Since this is a specific regulatory disclosure of a material event (clinical trial progress) that does not fit into categories like financial reports, dividends, or director dealings, it falls under the general regulatory filing category.
2022-08-24 Korean
반기보고서 (2022.06)
Interim / Quarterly Report Classification · 100% confidence The document is a '반기보고서' (Semi-Annual Report) for the company 'Curacle' (주식회사 큐라클) covering the period from January 1, 2022, to June 30, 2022. It contains detailed financial information, business operations, research and development activities, and management discussions, which aligns with the definition of an Interim/Quarterly Report (IR). H1 2022
2022-08-16 Korean
임원ㆍ주요주주특정증권등소유상황보고서
Director's Dealing Classification · 100% confidence The document is titled '임원ㆍ주요주주 특정증권등 소유상황보고서' (Report on Ownership of Specific Securities by Executives and Major Shareholders). It details the shareholding changes of an individual (Pyo Jung-in) who is an executive at Curacle. This is a standard regulatory filing for insider trading/director dealings in the Korean market, which corresponds to the 'Director's Dealing' category.
2022-08-05 Korean
주식등의대량보유상황보고서(일반)
Major Shareholding Notification Classification · 100% confidence The document is a '주식등의 대량보유상황보고서' (Report on Large Shareholding of Stocks, etc.), which is a standard regulatory filing in South Korea under the Capital Markets Act. It details changes in share ownership by major shareholders and their special relations, including market sales and changes in special relationship status. This corresponds to the 'Major Shareholding Notification' category.
2022-07-29 Korean
임시주주총회결과
Declaration of Voting Results & Voting Rights Announcements Classification · 100% confidence The document is a formal announcement of the results of an Extraordinary General Meeting (EGM) for the company Curacle. It explicitly lists the agenda items (appointment of an auditor) and the outcome (approved/passed). This falls under the category of Declaration of Voting Results, as it reports the official outcome of shareholder voting at a general meeting.
2022-07-22 Korean

Browse filings by year

7 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.